Share:
Share this content in WeChat
X
• Review •
Research progress of radiomics in predicting treatment response and prognosis of hepatocellular carcinoma after TACE
GAO Kexin  HE Tingting  XING Lihong 

DOI:10.12015/issn.1674-8034.2026.11.024.


[Abstract] Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the liver. Transcatheter arterial chemoembolization (TACE) serves as the first-line treatment for intermediate to advanced HCC; however, significant interindividual variability exists in treatment response and long-term prognosis. Radiomics enables non-invasive characterization of intratumoral and peritumoral microenvironmental features, and its integration with deep learning, habitat analysis, and multi-omics data facilitates the construction of predictive models. Nevertheless, current studies still face notable limitations in terms of standardization of image acquisition, feature reproducibility, prospective validation, and biological interpretability. Future efforts should focus on promoting deep integration of multimodal imaging and artificial intelligence, elucidating the biological mechanisms underlying radiomic features, and enhancing model generalizability through multicenter prospective cohort validation. This review systematically summarizes conventional imaging and clinical assessment approaches, as well as radiomics-based research advances in predicting TACE treatment outcomes in HCC patients, analyzes current challenges, and proposes future directions. It aims to provide imaging-based references for precise identification of TACE beneficiaries, early recognition of ineffective treatment, and individualized therapeutic decision-making, thereby facilitating the clinical translation of radiomics.
[Keywords] hepatocellular carcinoma;transcatheter arterial chemoembolization;efficacy prediction;radiomics;magnetic resonance imaging

GAO Kexin1, 2   HE Tingting1, 2   XING Lihong1, 2*  

1 Department of Radiology, Affiliated Hospital of Hebei University, Baoding 071000, China

2 Hebei Key Laboratory of Precise Imaging of Inflammation Related Tumors, Baoding 071000, China

Corresponding author: XING L H, E-mail: xlh86@hbu.edu.cn

Conflicts of interest   None.

Received  2026-03-27
Accepted  2026-09-10
DOI: 10.12015/issn.1674-8034.2026.11.024
DOI:10.12015/issn.1674-8034.2026.11.024.

[1]
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]
BARTNIK K, KRZYZIŃSKI M, BARTCZAK T, et al. A novel radiomics approach for predicting TACE outcomes in hepatocellular carcinoma patients using deep learning for multi-organ segmentation[J/OL]. Sci Rep, 2024, 14: 14779 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/38926517/. DOI: 10.1038/s41598-024-65630-z.
[3]
MASTHOFF M, IRLE M, KALDEWEY D, et al. Integrating CT radiomics and clinical features to optimize TACE technique decision-making in hepatocellular carcinoma[J/OL]. Cancers, 2025, 17(5): 893 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/40075740/. DOI: 10.3390/cancers17050893.
[4]
CHAKRABORTY E, SARKAR D. Emerging therapies for hepatocellular carcinoma (HCC)[J/OL]. Cancers, 2022, 14(11): 2798 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/35681776/. DOI: 10.3390/cancers14112798.
[5]
VOGEL A, MARTINELLI E, ESMO GUIDELINES COMMITTEE ELECTRONIC ADDRESS: CLINICALGUIDELINES@ESMO ORG, et al. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2021, 32(6): 801-805. DOI: 10.1016/j.annonc.2021.02.014.
[6]
REIG M, FORNER A, RIMOLA J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update[J]. J Hepatol, 2022, 76(3): 681-693. DOI: 10.1016/j.jhep.2021.11.018.
[7]
LUO X, LIU S W, HAI L, et al. Comparison of efficacy and safety of TACE and DEB-TACE in treatment of patients with unresectable hepatocellular carcinoma[J]. Chin J Hepatobiliary Surg, 2023, 29(3): 165-169. DOI: 10.3760/cma.j.cn113884-20221001-00376.
[8]
WEI Z Q, ZHANG Y W. Transcatheter arterial chemoembolization followed by surgical resection for hepatocellular carcinoma: a focus on its controversies and screening of patients most likely to benefit[J]. Chin Med J, 2021, 134(19): 2275-2286. DOI: 10.1097/CM9.0000000000001767.
[9]
LI X M, LIANG X J, CHEN S T, et al. Development and validation of a CT-based online calculator for prognosis and postoperative adjuvant transcatheter arterial chemoembolization benefit prediction in resected hepatocellular carcinoma: a multicenter retrospective cohort study[J/OL]. Int J Surg, 2025 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/41376483/. DOI: 10.1097/JS9.0000000000004456.
[10]
YU H L, BAI Y P, XIE X Y, et al. RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis[J/OL]. BMJ Open, 2022, 12(6): e052294 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/35649603/. DOI: 10.1136/bmjopen-2021-052294.
[11]
LAMBIN P, LEIJENAAR R T H, DEIST T M, et al. Radiomics: the bridge between medical imaging and personalized medicine[J]. Nat Rev Clin Oncol, 2017, 14(12): 749-762. DOI: 10.1038/nrclinonc.2017.141.
[12]
ZHU Y M, LIU T, CHEN J W, et al. Prediction of therapeutic response to transarterial chemoembolization plus systemic therapy regimen in hepatocellular carcinoma using pretreatment contrast-enhanced MRI based habitat analysis and Crossformer model[J]. Abdom Radiol, 2025, 50(6): 2464-2475. DOI: 10.1007/s00261-024-04709-7.
[13]
DENG K G, CHEN T, LENG Z J, et al. Radiomics as a tool for prognostic prediction in transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis[J]. La Radiol Med, 2024, 129(8): 1099-1117. DOI: 10.1007/s11547-024-01840-9.
[14]
WANG Y X, LI M, ZHANG Z, et al. Application of radiomics in the efficacy evaluation of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis[J]. Acad Radiol, 2024, 31(1): 273-285. DOI: 10.1016/j.acra.2023.08.001.
[15]
HUANG Z P, LI Z K, LV X L, et al. Screening of candidate inflammatory markers of epithelial cells in hepatocellular carcinoma based on integration analysis of TCGA/ICGC databases and single-cell sequencing[J]. Recent Pat Anticancer Drug Discov, 2025, 20(3): 364-384. DOI: 10.2174/0115748928256530240124093759.
[16]
YANG J C, SHEN X F. Evaluation value of three-phase dynamic enhanced CT scan for lesion residue and recurrence in patients with liver cancer after interventional chemoembolization[J]. Chin J CT MRI, 2025, 23(5): 102-104. DOI: 10.3969/j.issn.1672-5131.2025.05.030.
[17]
Department of Medical Administration, National Health Commission of the People's Republic of China. Guideline for diagnosis and treatment of primary liver cancer (2024 edition)[J]. Chin J Magn Reson Imaging, 2024, 15(6): 1-18. DOI: 10.12015/issn.1674-8034.2024.06.001.
[18]
WANG D D, ZHANG J F, ZHANG L H, et al. Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study[J]. Hepatobiliary Pancreat Dis Int, 2023, 22(6): 594-604. DOI: 10.1016/j.hbpd.2022.11.005.
[19]
FEZOULIDIS N, SLAVICEK J, NONNINGER J N, et al. Quantitative CT perfusion and radiomics reveal complementary markers of treatment response in HCC patients undergoing TACE[J/OL]. Diagnostics (Basel), 2025, 15(23): 2952 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/41374333/. DOI: 10.3390/diagnostics15232952.
[20]
TOMASZEWSKI M R, GILLIES R J. The biological meaning of radiomic features[J]. Radiology, 2021, 298(3): 505-516. DOI: 10.1148/radiol.2021202553.
[21]
LI Z W, REN A H, YANG D W, et al. Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features[J/OL]. BMC Med Imaging, 2022, 22(1): 176 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/36207686/. DOI: 10.1186/s12880-022-00900-8.
[22]
WANG D D, LI X M, YANG L, et al. Evaluation and prediction of therapeutic effect of hepatocellular carcinoma after TACE based on contrast enhanced MRI histogram analysis[J]. Chin J Magn Reson Imaging, 2024, 15(1): 113-118, 131. DOI: 10.12015/issn.1674-8034.2024.01.018.
[23]
TIAN Y C, KOMOLAFE T E, CHEN T, et al. Prediction of TACE treatment response in a preoperative MRI via analysis of integrating deep learning and radiomics features[J]. J Med Biol Eng, 2022, 42(2): 169-178. DOI: 10.1007/s40846-022-00692-w.
[24]
KANG W D, TANG P Y, LUO Y G, et al. Multiparametric MRI-based machine learning radiomics for predicting treatment response to transarterial chemoembolization combined with targeted and immunotherapy in unresectable hepatocellular carcinoma: a multicenter study[J]. Acad Radiol, 2025, 32(4): 2013-2026. DOI: 10.1016/j.acra.2024.10.038.
[25]
FENG L J, CHEN Q J, HUANG L J, et al. Radiomics features of computed tomography and magnetic resonance imaging for predicting response to transarterial chemoembolization in hepatocellular carcinoma: a meta-analysis[J/OL]. Front Oncol, 2023, 13: 1194200 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/37519801/. DOI: 10.3389/fonc.2023.1194200.
[26]
ZWANENBURG A, VALLIÈRES M, ABDALAH M A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping[J]. Radiology, 2020, 295(2): 328-338. DOI: 10.1148/radiol.2020191145.
[27]
HUANG Y H, QIAN H W. Advancing hepatocellular carcinoma management through peritumoral radiomics: enhancing diagnosis, treatment, and prognosis[J]. J Hepatocell Carcinoma, 2024, 11: 2159-2168. DOI: 10.2147/JHC.S493227.
[28]
ZHAO Y, ZHANG J, WANG N, et al. Intratumoral and peritumoral radiomics based on contrast-enhanced MRI for preoperatively predicting treatment response of transarterial chemoembolization in hepatocellular carcinoma[J/OL]. BMC Cancer, 2023, 23(1): 1026 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/37875815/. DOI: 10.1186/s12885-023-11491-0.
[29]
LI J Y, ZHOU M H, TONG Y H, et al. Tumor growth pattern and intra- and peritumoral radiomics combined for prediction of initial TACE outcome in patients with primary hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2024, 11: 1927-1944. DOI: 10.2147/JHC.S480554.
[30]
HASHIMOTO K, HARAGUCHI T, NAWATA S, et al. Creation of a prediction model of local tumor recurrence after a successful conventional transcatheter arterial chemoembolization using cone-beam computed tomography based–radiomics[J]. CardioVascular Interv Radiol, 2024, 47(11): 1495-1505. DOI: 10.1007/s00270-024-03854-2.
[31]
YANG H, LI H, CAO G F, et al. CT-based radiomics for predicting the therapeutic effect of hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. Chin J Med Imaging, 2025, 33(3): 252-259. DOI: 10.3969/j.issn.1005-5185.2025.03.006.
[32]
FAVE X, ZHANG L F, YANG J Z, et al. Delta-radiomics features for the prediction of patient outcomes in non–small cell lung cancer[J/OL]. Sci Rep, 2017, 7: 588 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/28373718/. DOI: 10.1038/s41598-017-00665-z.
[33]
HO L M, LAM S K, ZHANG J, et al. Association of multi-phasic MR-based radiomic and dosimetric features with treatment response in unresectable hepatocellular carcinoma patients following novel sequential TACE-SBRT-immunotherapy[J/OL]. Cancers, 2023, 15(4): 1105 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/36831445/. DOI: 10.3390/cancers15041105.
[34]
ZHOU W, LV Y Z, HU X M, et al. Study on the changes of CT texture parameters before and after HCC treatment in the efficacy evaluation and survival predication of patients with HCC[J/OL]. Front Oncol, 2022, 12: 957737 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/36387217/. DOI: 10.3389/fonc.2022.957737.
[35]
REN Z Z, WANG Y Q, JIANG D D, et al. PD1+ Treg cell remodeling promotes immune homeostasis within peripheral blood and tumor microenvironment after microparticles-transarterial chemoembolization in hepatocellular carcinoma[J/OL]. Cancer Immunol Immunother, 2025, 74(3): 109 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/39937280/. DOI: 10.1007/s00262-025-03962-z.
[36]
PINTO E, PELIZZARO F, CARDIN R, et al. HIF-1α and VEGF as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization[J]. Dig Liver Dis, 2024, 56(5): 872-879. DOI: 10.1016/j.dld.2023.09.019.
[37]
BOLDANOVA T, FUCILE G, VOSSHENRICH J, et al. Supervised learning based on tumor imaging and biopsy transcriptomics predicts response of hepatocellular carcinoma to transarterial chemoembolization[J/OL]. Cell Rep Med, 2021, 2(11): 100444 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/34841291/. DOI: 10.1016/j.xcrm.2021.100444.
[38]
CHEN M Z, ZHAO Z W, ZHOU L L, et al. MRI-based deep learning model for early TACE response prediction in HCC: multicenter validation with biological insights[J/OL]. BMC Cancer, 2025, 25(1): 1810 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/41286665/. DOI: 10.1186/s12885-025-15273-8.
[39]
FENG Z C, LI H L, LIU Q Y, et al. CT radiomics to predict macrotrabecular-massive subtype and immune status in hepatocellular carcinoma[J/OL]. Radiology, 2023, 307(1): e221291 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/36511807/. DOI: 10.1148/radiol.221291.
[40]
WANG W L, ZHANG S H, ZHONG B Y, et al. Dynamic changes of radiological and radiomics patterns based on MRI in viable hepatocellular carcinoma after transarterial chemoembolization[J]. Abdom Radiol (NY), 2025, 50(5): 2110-2120. DOI: 10.1007/s00261-024-04676-z.
[41]
JIN Z C, WEI J W, XIAO Y D, et al. Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204)[J/OL]. Hepatology, 2025 [2026-02-17]. https://pubmed.ncbi.nlm.nih.gov/41213031/. DOI: 10.1097/HEP.0000000000001593.
[42]
Clinical Guidelines Committee of Chinese College of Interventionalists. Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma (2023 edition)[J]. Natl Med J China, 2023, 103(34): 2674-2694. DOI: 10.3760/cma.j.cn112137-20230630-01114.
[43]
ZHANG S, ZHONG B Y, ZHANG L, et al. Transarterial chemoembolization failure/refractoriness: a scientific concept or pseudo-proposition[J]. World J Gastrointest Surg, 2022, 14(6): 528-537. DOI: 10.4240/wjgs.v14.i6.528.
[44]
DONG Y H, HU J H, MENG X R, et al. Development and validation of a radiomics nomogram based on magnetic resonance imaging and clinicoradiological factors to predict HCC TACE refractoriness[J]. Cancer Manag Res, 2025, 17: 1441-1455. DOI: 10.2147/CMAR.S486561.
[45]
XIAO Y, SONG W L, LIU H, et al. Can incorporating preoperative arterial enhancement ratio map into habitat analysis predict TACE refractoriness in unresectable hepatocellular carcinoma[J/OL]. BMC Med Imaging, 2026, 26(1): 322 [2026-06-06]. https://pubmed.ncbi.nlm.nih.gov/42106669/. DOI: 10.1186/s12880-026-02371-7.
[46]
LI M X, QIN L, QIU Z C, et al. Alpha fetoprotein-tumor burden score predicts prognosis of patients with hepatocellular carcinoma after hepatectomy: a multicenter retrospective cohort study[J]. Chin J Bases Clin Gen Surg, 2025, 32(2): 192-198.
[47]
ZHOU L L, ZHENG L Y, ZHANG K, et al. Radiomic biomarkers for the recurrence prediction of hepatocellular carcinoma treated with postoperative TACE: A multicenter retrospective study[J/OL]. Eur J Radiol, 2025, 193: 112442 [2026-06-06]. https://pubmed.ncbi.nlm.nih.gov/41033016/. DOI: 10.1016/j.ejrad.2025.112442.
[48]
ZHANG S H, WANG W L, CAI W, et al. MR radiomics combined with radiologic features to predict recurrence location in nonviable hepatocellular carcinoma after transarterial chemoembolization[J]. J Gastroenterol Hepatol, 2026, 41(5): 1573-1582. DOI: 10.1111/jgh.70325.
[49]
YANG G H, CHEN Y X, WANG M L, et al. Impact of microvascular invasion risk on tumor progression of hepatocellular carcinoma after conventional transarterial chemoembolization[J/OL]. Oncologist, 2025, 30(2): oyae286 [2026-06-06]. https://pubmed.ncbi.nlm.nih.gov/39475355/. DOI: 10.1093/oncolo/oyae286.
[50]
PENG G, CAO X J, HUANG X Y, et al. Radiomics and machine learning based on preoperative MRI for predicting extrahepatic metastasis in hepatocellular carcinoma patients treated with transarterial chemoembolization[J/OL]. Eur J Radiol Open, 2024, 12: 100551 [2026-06-06]. https://pubmed.ncbi.nlm.nih.gov/38347937/. DOI: 10.1016/j.ejro.2024.100551.
[51]
LIU C L, HAN L, DING X, et al. Development of a predictive model for distant metastasis in HCC patients post-TACE using clinical data, radiomics, and deep learning[J/OL]. J Cancer Res Clin Oncol, 2025, 151(10): 258 [2026-06-06]. https://pubmed.ncbi.nlm.nih.gov/40954349/. DOI: 10.1007/s00432-025-06308-5.
[52]
GUO Y S, ZHANG G L, FU X N, et al. Hypoxia-related and immune phenotype-related fusion model for non-invasive prognostication of hepatocellular carcinoma treated by TACE: a multicentre study[J/OL]. Gut, 2026: gutjnl-gu2025-337938 [2026-03-23]. https://pubmed.ncbi.nlm.nih.gov/41856522/. DOI: 10.1136/gutjnl-2025-337938.
[53]
LIU Q P, YANG K L, XU X, et al. Radiomics analysis of pretreatment MRI in predicting tumor response and outcome in hepatocellular carcinoma with transarterial chemoembolization: a two-center collaborative study[J]. Abdom Radiol, 2022, 47(2): 651-663. DOI: 10.1007/s00261-021-03375-3.
[54]
SONG W L, YU X L, GUO D J, et al. MRI-based radiomics: associations with the recurrence-free survival of patients with hepatocellular carcinoma treated with conventional transcatheter arterial chemoembolization[J]. J Magn Reson Imaging, 2020, 52(2): 461-473. DOI: 10.1002/jmri.26977.
[55]
GUAN Q L, ZHANG H X, REN W X, et al. Habitat image based on enhanced MRI before transcatheter arterial chemoembolization of hepatocellular carcinoma clinical value of prognosis prediction[J/OL]. J Radiat Res Appl Sci, 2025, 18(3): 101666 [2026-03-23]. https://www.sciencedirect.com/science/article/pii/S1687850725003784via%3Dihub. DOI: 10.1016/j.jrras.2025.101666.
[56]
IVANICS T, SALINAS-MIRANDA E, ABREU P, et al. A pre-TACE radiomics model to predict HCC progression and recurrence in liver transplantation: a pilot study on a novel biomarker[J]. Transplantation, 2021, 105(11): 2435-2444. DOI: 10.1097/TP.0000000000003605.
[57]
LI L L, KAN X F, ZHAO Y J, et al. Radiomics Signature: a potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma[J]. Int J Med Sci, 2021, 18(11): 2276-2284. DOI: 10.7150/ijms.55510.
[58]
KANG W D, LUO Y G, ZHOU X, et al. Multiparametric MRI-based deep learning and radiomics for predicting progression-free survival benefit in patients with hepatocellular carcinoma treated with immunotherapy and targeted therapy plus transarterial chemoembolization: A bicentric study[J]. Acad Radiol, 2026, 33(6): 2428-2441. DOI: 10.1016/j.acra.2026.01.059.
[59]
WANG J, LIU H, LI Y M, et al. Deep-learning radiomics and hand-crafted radiomics utilizing contrast-enhanced MRI to predict early peritumoral recurrence after DEB-TACE with hepatocellular carcinoma: a two-center study[J/OL]. Front Oncol, 2025, 15: 1642828 [2026-03-23]. https://pubmed.ncbi.nlm.nih.gov/41341387/. DOI: 10.3389/fonc.2025.1642828.
[60]
XI Z H, YE Y X, YANG Y B, et al. Radiomics analysis based on contrast-enhanced MRI for predicting short-term efficacy of drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma[J]. Abdom Radiol, 2024, 49(7): 2387-2400. DOI: 10.1007/s00261-024-04319-3.
[61]
WEI N, MATHY R M, CHANG D H, et al. Longitudinal CE-MRI-based Siamese network with machine learning to predict tumor response in HCC after DEB-TACE[J/OL]. Cancer Imaging, 2025, 25(1): 104 [2026-03-23]. https://pubmed.ncbi.nlm.nih.gov/40830494/. DOI: 10.1186/s40644-025-00926-5.
[62]
KONG C L, ZHAO Z W, CHEN W Y, et al. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE[J]. Eur Radiol, 2021, 31(10): 7500-7511. DOI: 10.1007/s00330-021-07910-0.

PREV Research progress of radiomics and deep learning in efficacy evaluation and prognosis prediction of liver malignant tumors
NEXT Research progress on MRI assessment of extramural vascular invasion in rectal cancer
  



Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn